## Docket No:3230.3000-US1 HE UNITED STATES PATENT AND TRADEMARK OFFICE John C. Salerno 10/712,806 Group Art Unit: 1646 Filed: November 13, 2003 Examiner: Not Assigned Confirmation No.: 7854 Title: Methods of Generating Chimera CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on: Date Signature Hollie Wakefield Typed or printed name of person signing certificate INFORMATION DISCLOSURE STATEMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or $[\ ]$ (First/Second submission after Final Rejection) [X] under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application, or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). [ ] under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or ſÌ (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) [ ] under 37 CFR.1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee) [ ] under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application

filewrapper. (Filed after payment of issue fee)

Statement	Under 37	CFR 1.97	(c)

[]	cited i applic	tem of information contained in this Information Disclosure Statement was first n any communication from a foreign patent office in a counterpart foreign ation not more than three months prior to the filing of this Information Disclosure nent; or	
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
		der 37 CFR 1.704(d) (Patent Term Adjustment) applications (other than design) filed on or after May 29, 2000)	
[]	a com	tem of information contained in the Information Disclosure Statement was cited in munication from a foreign patent office in a counterpart application and this unication was not received by any individual designated in -§ 1.56(c) more than days prior to the filing of the Information Disclosure Statement.	
[ X ]	Enclos	sed herewith is form PTO-1449: Copies of the cited references are enclosed.	
	[]	Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]	
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.	
	[]	The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by: [ ] the explanation provided on the attached sheet. [ ] the explanation provided in the Specification. [ ] submission of the enclosed International Search Report. [ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action. [ ] the enclosed English language abstract.	

The Examiner is requested to return a copy of the list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

## Method of payment:

[]	A check for the fee noted above is enclosed, or the fee has been included in the check
	with the accompanying Reply. A copy of this Statement is enclosed.
[]	Please charge Deposit Account [ ] in the amount of [\$ ]. A copy of this Statement is enclosed.
[]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 502807.

Respectfully submitted,

ELMORE CRAIG, P.C.

Carolyn S. Elmore

Registration No.: 37,567 Telephone: (978) 251-3509 Facsimile: (978) 251-3973

N. Chelmsford, MA 01863

Dated:

PTO-1449 REPRODUCED

JUN 2 1 2004

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION COPENDS March 1, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 3230.3000 US1

application no. 10/712,806

APPLICANT

John C. Salerno

FILING DATE
November 13, 2003

CONFIRMATION NO. 7854

group 1646

		U	.s. patent documents	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AA	6,303,290 B1	16 Oct 2001	Liu et al.
	АВ	6,051,380	18 Apr 2000	Sosnowski et al.
	AC	5,854,030	29 Dec 1998	Dordick et al.
	AD	5,824,526	20 Oct 1998	Avnir et al.
	AE	5,618,933	08 Apr 1997	Dordick et al.
	AF	5,474,915	12 Dec 1995	Dordick et al.
	AG	5,200,334	06 Apr 1993	Dunn et al.
	АН	3,650,900	21 Mar 1972	Levin et al.
	AA2	2002/0028506 A1	07 Mar 2002	Ho et al.
	AB2	2002/0020931 A1	21 Feb 2002	Stowell et al.
	AC2	2002/0015952 A1	07 Feb 2002	Anderson et al.
	AD2	2001/0055797 A1	27 Dec 2001	Conroy et al.
	AE2			
	AF2			
	AG2			
	AH2			
	AA3			
	AB3			
	AC3			
	AD3			
	AE3			
	AF3			
	AG3			

	EXAMINER	DATE CONSIDERED
l		

,

PTO-1449 REPRODUCED

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

March 1, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 3230.3000 US1	application no. 10/712,806	
APPLICANT John C. Salerno		

7854

CONFIRMATION NO.

GROUP

1646

	<del>-</del>	FOREIGN PATENT D	OCUMENTS	
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
AL	WO 00/54882	21 Sep 2000	PCT	
AM	WO 00/54882 A1	21 Sep 2000	PCT	
AN	WO 03/038131 A1	08 May 2003	PCT	
AO				
AP				
AQ				
AL2				
AM2				
AN2				
AO2				
AP2				
AQ2				
AL3				
AM3				
AN3				
AO3				
AP3				
AQ3				
AL4				
AM4				
AN4				
AO4				

FILING DATE

November 13, 2003

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO. 3230.3000 US1 10/712,806

INFORMATION DISCLOSURE CITATION IN AN APPLICATION APPLICATION John C. Salerno

March 1, 2004

FILING DATE

CONFIRMATION NO. GROUP

November 13, 2003

7854

1646

(Use several sheets if necessary)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AR	Chauret, N. et al., "Description of a 96-well plate assay to measure cytochromes p4503 A inhibition in human liver microsomes using a selective fluorescent probe," Anal. Biochem. 276:215-226 (1999).
AS	Crespi, C.L. et al., "Microtiter plate assays for inhibition of human, drug-metabolism cytochromes P450," Anal. Biochem., 248:188-190 (1997).
АТ	Gill, I. et al., "Encapsulation of biologicals within silicate, siloxane, and hybrid sol-gel polymers: an efficient and generic approach," J. Am. Chem. Soc., 120(34):8587-8598 (1998).
AU	Gill, I. et al., "Bioencapsulation within synthetic polymers (Part 1): sol-gel encapsulated biologicals," <i>TIBTECH</i> , <b>18</b> :282-296 (2000).
AV	Iwatsubo, T. et al., "Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data," <i>Pharmacol. Ther.</i> , 73:147-171 (1997).
AW	Kim, Y. et al., "Stable sol-gel microstructured and microfluidic networks for protein patterning," Biotechnology & Bioengineering, 73(5): 331-337 (2001).
AX	Kim, J. et al., "Protease-containing silicates as active antifouling materials," Biotechnology Prog., 18(3):551-555 (2002).
AY	Lake, B.G. et al., "Induction of CYP3A Isoforms in cultured precision-cut human liver slices," Xenobiotica, 27:1165-1173 (1997).
AZ	Nagy, G. et al., "Amperometric microcell for enzyme activity measurements," Analytical Chemistry, 70(10):2156-2162 (1998).
AR2	Novick, S.J. et al., "Preparation of active and stable biocatalytic hydrogels for use in selective transformations," <i>Chemistry of Materials</i> , 10(4):955-958 (1998).
AS2	Novick, S.J. et al., "Investigating the effects of polymer chemistry on activity of biocatalytic plastic materials," <i>Biotechnology and Bioengineering</i> , <b>68(6)</b> :665-671 (2000).
AT2	Park, C.B. et al., "Sol-gel encapsulated enzyme arrays for high-throughput screening of biocatalytic activity," Biotechnology & Bioengineering, 78(2):229-235 (2002).
AU2	Sergeeva, M.V. et al., "Peptide synthesis using proteases dissolved in organic solvents," Enzyme Microbial. Technology, 20:623-628 (1997).
AV2	Silber, P.M. et al., "In vitro methods for predicting human toxicity," Lab Animal, 23:33-37 (1994).
AW2	Wang, P. et al., "Biocatalytic plastics as active and stable materials for biotransformations," <i>Nature Biotechnology</i> , <b>15</b> :789-793 (1997).
AX2	Zomorodi, K. et al., "Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance," Xenobiotica, 25:907-916 (1995).

EXAMINER	DATE CONSIDERED